Eradication of Pseudomonas aeruginosa in cystic fibrosis.
Eber
E
E
Thalhammer
G H
GH
Zach
M S
MS
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000382:microbiology* / Q000503:physiopathology; D004334:Drug Administration Schedule; D016527:Drug Costs; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D012008:Recurrence; D012129:Respiratory Function Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents